Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Entities / ARD-101
Other

ARD-101

Tracked across 1 events · 6 articles · First seen May 21, 2026 · Last active May 26, 2026

Sentiment
-80
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 -80
Regulatory
Pomerantz Investigates Aardvark Therapeutics Securities Fraud
Pomerantz LLP is investigating MiNK Therapeutics for securities fraud after the company's stock price plummeted following two major announcements. On February 27, 2026, MiNK Therapeutics voluntarily paused its Phase 3 HERO trial for ARD-101 due…
Impact: ARD-101 is the investigational drug developed by MiNK Therapeutics, which is now under a full clinical hold by the United States — Food and Drug Administration, severely impacting its development and market potential.
May 21, 2026 · 6 articles
NEWSDESK
Track ARD-101 live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.